Progression of parkinsonism and loss of cognitive function in Alzheimer disease

Archives of Neurology

Volumn 57, Issue 6, 2000, Pages 855-860

  Wilson, Robert S ^a   Bennett, David A ^a   Gilley, David W ^a   Beckett, Laurel A ^b   Schneider, Julie A ^a   Evans, Denis A ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; PARKINSONISM; PRIORITY JOURNAL;

EID: 0034099648     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.6.855     Document Type: Article

References (49)

1. Burns A, Jacoby R, Levy R. Neurological sings in Alzheimer's disease. Age Ageing. 1991;20:45-51.
2. Chui H, Teng E., Henderson V, Moy A. Clinical subtypes of dementia in Alzheimer's disease. Neurology. 1985;35:1544-1550.
3. Clark C, Ewbank D, Lerner A. et al. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD study. Neurology. 1997;49:70-75.
4. Girling D, Berrios G. Extrapyramidal signs, primitive reflexes and frontal lobe function in senile dementia of the Alzehimer type. Br J Psychiatry. 1990;157:888-893.
5. Lopez O, Wisnieski S, Becker J, Boller F, DeKosky S. Extrapyramidal signs in patients with probable Alzheimer's disease. Arch Neurol. 1997;54:969-975.
6. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of Alzheimer's type: evidence for subgroups. Neurology. 1985;35:453-461.
7. Morris J, Drazner M, Fulling K, Grant E, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. Arch Neurol. 1989;46:651-657.
8. Richards M, Bell K, Dooneief M, et al. Patterns of neuropsychological performance in Alzheimer's disease patients with and without extrapyramidal signs. Neurology. 1993;43:1708-1711.
9. Richards M, McLoughlin D, Levy R. The relationship between extrapyramidal signs and cognitive function in patients with moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry. 1995;10:395-399.
10. Stern Y, Mayeux R, Sano M, Hauser W, Bush T. Predictors of disease course in patients with probable Alzheimer's disease. Neurology. 1987;37:1649-1653.
11. Richards M, Folstein M, Albert M, et al. Multicenter study of disease course in Alzheimer's disease (the "Predictors Study"), II: neurologic, psychiatric, and demographic influences on baseline measures of disease severity. Alzheimer Dis Assoc Disord. 1993;7:22-32.
12. Snowden M, Bowen J, Hughes J, Larson E. Study of Alzheimer's dementia patients with parkinsonian features. J Geriatr Psychiatry Neurol. 1995;8:154-158.
13. Galasko D, Kwo-on-Yuen P, Klauber M, Thal L. Neurological findings in Alzheimer's disease and normal aging. Arch Neurol. 1990;47:625-627.
14. Soininen H, Helkala E-L, Laulumaa R, Soikkeli P, Hartikainen P, Riekkinen P. Cognitive profile of Alzheimer patients with extrapyramidal signs: a longitudinal study. J Neurol Transm. 1992;4:241-254.
15. Miller T, Tinklenberg J, Brooks J, Yesavage J. Cognitive decline in patients with Alzheimer's disease: differences in patients with and without extrapyramidal signs. Alzheimer Dis Assoc Disord. 1991;5:2151-253.
16. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the predictors study. Neurology. 1994;44:2300-2307.
17. Chui H, Lyness S, Sobel E, Schneider L. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol. 1994;51:676-681.
18. Corey-Bloom J, Galasko D, Hofstetter R, Jackson J, Thai L. Clinical features distinguishing large cohorts with possible AD probable AD, and mixed dementia. J Am Geriatr Soc. 1993;41:31-37.
19. Mortimer J, Ebbitt B, Jun S-P, Finch M. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology, 1992;42: 1689-1696.
20. Stern Y, Liu X, Albert M, et al. Modeling the influence of extrapyramidal signs on the progression of Alzheimer's disease. Arch Neurol. 1996;53:1121-1126.
21. Chen J-Y, Stern Y, Sano M, Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol. 1991;48:1141-1143.
22. Soininen H, Laulumaa V, Helkala E, Hartikainen P, Riekkinen P. Extrapyramidal signs in Alzheimer's disease: a 3-year follow-up study. J Neurol Transm. 1992; 4:107-119.
23. Wilson R, Bennett D, Gilley D, Beckett L, Schneider J, Evans D. Progression of parkinsonian signs in Alzheimer's disease. Neurology. 2000;54:1284-1259.
24. Wilson R, Gilley D, Bennett D, Beckett L, Evans D. Person-specific paths of cognitive decline in Alzheimer's disease and their relation to age. Psychol Aging. 2000; 15:18-28.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
26. Folstein M, Folstein S, McHugh P. "Mini-mental state": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res. 1975;12: 189-198.
27. Medi-Span Inc. Master Drug Data Base Documentation Manual. Indianapolis, Ind: Medi-Span Inc, 1995.
28. Mirra S, Hart M, Terry R. Making the diagnosis of Alzheimer's disease: a primer for practicing pathologists. Arch Pathol Lab Med. 1993; 117:132-144.
29. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S. Marsden C. Goldstein M, Calne D, eds. Recent Developments in Parkinson's Disease. Vol 12. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
30. Bennett D, Shannon K, Beckett L, Goetz C, Wilson R. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology. 1997:49:1580-1586.
31. Bennett D, Shannon K, Beckett L, Wilson R. Dimensionality of parkinsonian signs in aging and Alzheimer's disease [research letter]. J Gerontol A Biol Sci Med Sci. 1999;54A:M191-M196.
32. Albert M, Smith L, Scherr P, Taylor J, Evans D, Funkenstein H. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci. 1991;57:167-178.
33. Morris J, Heyman A, Mohs R, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989:39:1159-1165.
34. Benton A, Sivan A, Hamsher K, Varney N, Spreen O. Contributions to Neuropsychological Assessment. New York, NY: Oxford University Press, 1994.
35. Goodlass H, Kaplan D. The Assessment of Aphasia and Related Disorders. 2nd ed. Philadelphia, Pa: Lea & Febiger, 1983.
36. Kukull W. Problems in measuring and interpreting cognitive decline. J Am Geriatr Soc. 1998;46:1578-1579.
37. Laird N, Ware J. Random-effects models for longitudinal data. Biometrics. 1982; 38:963-974.
38. Beckett L, Gilley D, Tancredi D. Modeling associations between change over time in multiple outcomes. 1998 Proceedings of the Section on Statistics in Epidemiology. Alexandria, Va: American Statistical Association: 1998:106-110.
39. SAS Institute Inc. SAS/STAT Software: Changes and Enhancements Through Release 6.12. Cary, NC: SAS Institute Inc. 1997.
40. Ellis R, Caligiuri M, Galasko D, Thal L. Extrapyramidal motor signs in clinically diagnosed Alzheimer's disease. Alzheimer Dis Assoc Disord. 1996;10:103-114.
41. Troncoso J, Cataldo A, Nixon R, et al. Neuropathology of preclinical and clinical late-onset Alzheimer's disease. Ann Neurol. 1998;43:673-676.
42. Liu Y, Stern Y, Chun M, Jacobs D, Yau P, Goldman J. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol. 1997;41:368-374.
43. Owen A, James M, Leigh P. et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain. 1992;115:1727-1751.
44. Jenner P. Oxidative damage in neurodegenerative disease Lancet. 1994;344: 796-798.
45. Mecocci P, MacGarvey U, Beal F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 1994;36:747-751.
46. Mortimer J, Pirozzolo F, Hansch E, Webster D. Relationship of motor symptoms to intellectual deficits in Parkinson's disease. Neurology. 1982;32:133-137.
47. Portin R, Koivusalo A, Laihinen A, Rinne U. Cognitive deficits, motor disability and duration of illness in early Parkinson's disease [abstract]. J Clin Exp Neuropsychology. 1989:11:369.
48. Zetusky W, Jankovic J, Pirozzolo F. The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology. 1985;35:522-526.
49. Linn R, Wolf P, Bachman D, et al. The "preclinical phase" of probable Alzheimer's disease: a 13-year prospective study of the Framingham cohort. Arch Neurol. 1995;52:485-490.